Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) agreed to engage China Resources Kelun as a downstream distributor and seller for some of its commercialized products from time to time during Oct. 31, 2024, and Dec. 31, 2025, a Thursday Hong Kong bourse filing said.
Under the agreement, the company will sell its commercialized products to the other party from time to time, which the other party will distribute downstream or sell directly to the consumers.
The annual caps set for the transactions are 10 million yuan for 2024 and 15 million yuan for 2025.